Organization
University of Massachusetts Medical School, Worcester, United States
4 abstracts
Abstract
“IS THIS REALLY THE WAY WE SHOULD GO?” – PATIENT PERSPECTIVES ON RHEUMATOID ARTHRITIS MANAGEMENT Org: Orthopedics, University of Massachusetts Medical School, Meyers Primary Care Institute, Worcester, Albany Medical College, Albany, Global Healthy Living Foundation, Upper Nyack, Johns Hopkins University, Baltimore, MD,
Abstract
APREMILAST IS ASSOCIATED WITH LONG-TERM (4-YEAR) DAS-28 (CRP) REMISSION AND IMPROVEMENTS IN SKIN DISEASE: RESULTS FROM A PHASE III STUDY IN DMARD/BIOLOGIC-EXPERIENCED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS Org: University Hospital Southampton, Southampton, United Kingdom, INIBIC-Hospital Universitario A Coruña, Galicia, Spain, Bakersfield Dermatology, Bakersfield, Celgene Corporation, Summit, University of Massachusetts Medical School, Worcester, United States,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS Org: University of California San Diego, San Diego, United States, University of Genova, Genova, Italy, Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, Toronto Western Hospital, Toronto, Canada, University of Sheffield, Sheffield, United Kingdom,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS INCLUDING CURRENT SKIN INVOLVEMENT: RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: University of Massachusetts Medical School, Worcester, United States, INIBIC-Hospital Universitario A Coruña, Galicia, Spain, Bakersfield Dermatology, Bakersfield, United States, Celgene Corporation, Warren, United States, University Hospital Southampton, Southampton, United Kingdom,